| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenergic beta-Antagonists | 25 | 2020 | 243 | 3.970 |
Why?
|
| Asthma | 25 | 2017 | 748 | 3.790 |
Why?
|
| Receptors, Adrenergic, beta-2 | 17 | 2018 | 84 | 2.740 |
Why?
|
| Nadolol | 12 | 2020 | 28 | 2.110 |
Why?
|
| Adrenergic beta-Agonists | 13 | 2020 | 94 | 1.840 |
Why?
|
| Propanolamines | 11 | 2017 | 32 | 1.340 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 9 | 2016 | 62 | 1.330 |
Why?
|
| Receptors, Adrenergic, beta | 10 | 2020 | 62 | 0.990 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 7 | 2020 | 13 | 0.870 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2022 | 292 | 0.760 |
Why?
|
| Propranolol | 6 | 2020 | 127 | 0.730 |
Why?
|
| Carbazoles | 5 | 2017 | 33 | 0.720 |
Why?
|
| Eosinophils | 2 | 2017 | 120 | 0.660 |
Why?
|
| Receptors, Adrenergic | 6 | 2020 | 29 | 0.610 |
Why?
|
| Drug Discovery | 2 | 2022 | 171 | 0.590 |
Why?
|
| Epithelial Cells | 3 | 2017 | 909 | 0.560 |
Why?
|
| Signal Transduction | 15 | 2020 | 4489 | 0.540 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2016 | 2 | 0.530 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 6 | 0.530 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2015 | 112 | 0.510 |
Why?
|
| Animals | 56 | 2020 | 34016 | 0.500 |
Why?
|
| Inflammation | 6 | 2017 | 1431 | 0.490 |
Why?
|
| Lung | 4 | 2017 | 1490 | 0.470 |
Why?
|
| Myocardium | 10 | 2003 | 997 | 0.470 |
Why?
|
| Mice, Inbred BALB C | 7 | 2017 | 1003 | 0.440 |
Why?
|
| Ligands | 11 | 2014 | 532 | 0.440 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 4344 | 0.420 |
Why?
|
| Exercise | 4 | 2020 | 817 | 0.420 |
Why?
|
| Mucins | 3 | 2015 | 74 | 0.410 |
Why?
|
| Albuterol | 2 | 2015 | 53 | 0.370 |
Why?
|
| Dexamethasone | 1 | 2011 | 276 | 0.330 |
Why?
|
| Ovalbumin | 5 | 2017 | 318 | 0.320 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 5 | 2015 | 158 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 287 | 0.320 |
Why?
|
| Mice | 24 | 2017 | 17570 | 0.310 |
Why?
|
| Epinephrine | 4 | 2020 | 179 | 0.310 |
Why?
|
| Glucocorticoids | 1 | 2011 | 381 | 0.310 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 153 | 0.300 |
Why?
|
| Mice, Transgenic | 14 | 2017 | 2384 | 0.280 |
Why?
|
| Metoprolol | 1 | 2007 | 22 | 0.280 |
Why?
|
| Myocardial Contraction | 5 | 2003 | 265 | 0.270 |
Why?
|
| Adrenergic alpha-Antagonists | 5 | 2001 | 48 | 0.270 |
Why?
|
| Alprenolol | 6 | 2015 | 10 | 0.270 |
Why?
|
| Interleukin-13 | 2 | 2017 | 97 | 0.260 |
Why?
|
| Bronchi | 2 | 2017 | 98 | 0.260 |
Why?
|
| Drug Information Services | 1 | 2005 | 7 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2011 | 1688 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 1998 | 469 | 0.250 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 31 | 0.250 |
Why?
|
| Research Design | 2 | 2015 | 693 | 0.240 |
Why?
|
| GTP-Binding Proteins | 5 | 1999 | 177 | 0.240 |
Why?
|
| Models, Biological | 3 | 2015 | 1458 | 0.230 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 2 | 2020 | 13 | 0.230 |
Why?
|
| Phenotype | 8 | 2020 | 4254 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 555 | 0.230 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2017 | 52 | 0.220 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2016 | 38 | 0.220 |
Why?
|
| Humans | 39 | 2022 | 124780 | 0.210 |
Why?
|
| Technology, Pharmaceutical | 1 | 2002 | 20 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 4366 | 0.200 |
Why?
|
| Thinking | 1 | 2002 | 36 | 0.200 |
Why?
|
| Coronary Vessels | 3 | 2003 | 541 | 0.200 |
Why?
|
| Male | 28 | 2020 | 61298 | 0.190 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2022 | 87 | 0.190 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2001 | 22 | 0.190 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2015 | 149 | 0.190 |
Why?
|
| Pharmacology, Clinical | 1 | 2001 | 5 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 1707 | 0.190 |
Why?
|
| Protein Transport | 1 | 2022 | 368 | 0.180 |
Why?
|
| Receptors, Serotonin | 3 | 1989 | 42 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2005 | 1177 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1163 | 0.170 |
Why?
|
| Muscle, Smooth | 5 | 2014 | 135 | 0.170 |
Why?
|
| Norepinephrine | 5 | 1993 | 175 | 0.170 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 280 | 0.170 |
Why?
|
| Graft vs Tumor Effect | 1 | 2020 | 7 | 0.170 |
Why?
|
| Formoterol Fumarate | 2 | 2016 | 31 | 0.160 |
Why?
|
| Methacholine Chloride | 3 | 2009 | 21 | 0.160 |
Why?
|
| Isoproterenol | 7 | 1999 | 106 | 0.160 |
Why?
|
| Drug Inverse Agonism | 2 | 2010 | 5 | 0.160 |
Why?
|
| Viruses | 1 | 2020 | 123 | 0.160 |
Why?
|
| Coronary Disease | 1 | 2003 | 674 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2014 | 815 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 158 | 0.160 |
Why?
|
| Ethanolamines | 3 | 2013 | 30 | 0.160 |
Why?
|
| Pharmacology | 1 | 1998 | 10 | 0.150 |
Why?
|
| Respiratory Function Tests | 2 | 2010 | 198 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 158 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2017 | 95 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2017 | 111 | 0.150 |
Why?
|
| Pyroglyphidae | 1 | 2017 | 9 | 0.140 |
Why?
|
| Arrestins | 2 | 2015 | 28 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 1265 | 0.140 |
Why?
|
| Xanthines | 2 | 2013 | 14 | 0.130 |
Why?
|
| Metaplasia | 1 | 2017 | 213 | 0.130 |
Why?
|
| Mucus | 1 | 2016 | 36 | 0.130 |
Why?
|
| Monocytes | 1 | 2018 | 351 | 0.130 |
Why?
|
| Cyclopropanes | 1 | 2016 | 68 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 327 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2016 | 55 | 0.130 |
Why?
|
| Benzamides | 1 | 2016 | 105 | 0.130 |
Why?
|
| Peptidomimetics | 1 | 2015 | 12 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 394 | 0.130 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2015 | 19 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 35 | 0.120 |
Why?
|
| Mucin 5AC | 1 | 2015 | 24 | 0.120 |
Why?
|
| Drug Design | 2 | 2007 | 147 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2020 | 750 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 558 | 0.120 |
Why?
|
| Research Report | 1 | 2015 | 75 | 0.120 |
Why?
|
| Bisoprolol | 3 | 2020 | 10 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2016 | 3715 | 0.120 |
Why?
|
| Editorial Policies | 1 | 2015 | 53 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 1548 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2017 | 1611 | 0.110 |
Why?
|
| Female | 16 | 2020 | 66592 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 414 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1532 | 0.110 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2014 | 348 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 1198 | 0.110 |
Why?
|
| Airway Resistance | 3 | 2014 | 36 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 323 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 205 | 0.110 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2013 | 3 | 0.110 |
Why?
|
| Kidney | 3 | 1989 | 1355 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 536 | 0.110 |
Why?
|
| Muscle Contraction | 6 | 2014 | 188 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 827 | 0.110 |
Why?
|
| Memory, Long-Term | 1 | 2013 | 41 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 198 | 0.100 |
Why?
|
| In Vitro Techniques | 8 | 1993 | 968 | 0.100 |
Why?
|
| Guinea Pigs | 6 | 1992 | 166 | 0.100 |
Why?
|
| Ileum | 6 | 1992 | 132 | 0.090 |
Why?
|
| Thiophenes | 1 | 1992 | 59 | 0.090 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2009 | 11 | 0.090 |
Why?
|
| Cytokines | 2 | 2020 | 1290 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2011 | 250 | 0.090 |
Why?
|
| Respiratory Mucosa | 1 | 2011 | 91 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2013 | 236 | 0.090 |
Why?
|
| Serotonin Antagonists | 2 | 1989 | 24 | 0.080 |
Why?
|
| Bronchoconstriction | 2 | 2015 | 17 | 0.080 |
Why?
|
| Mutation | 6 | 2014 | 5824 | 0.080 |
Why?
|
| Catecholamines | 2 | 2020 | 58 | 0.080 |
Why?
|
| HEK293 Cells | 3 | 2022 | 736 | 0.080 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 602 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 1697 | 0.080 |
Why?
|
| Heart Failure | 5 | 2007 | 2285 | 0.080 |
Why?
|
| Cardiomegaly | 2 | 2003 | 130 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2286 | 0.080 |
Why?
|
| Adult | 6 | 2020 | 29510 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2520 | 0.080 |
Why?
|
| Indoles | 1 | 1989 | 179 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 52 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 73 | 0.070 |
Why?
|
| Heart | 4 | 1997 | 710 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2007 | 33 | 0.070 |
Why?
|
| Bronchial Provocation Tests | 1 | 2007 | 14 | 0.070 |
Why?
|
| Sulfonamides | 1 | 1989 | 261 | 0.070 |
Why?
|
| Rats | 6 | 2020 | 3674 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 1023 | 0.070 |
Why?
|
| Serotonin | 4 | 1995 | 219 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 691 | 0.070 |
Why?
|
| Electric Stimulation | 5 | 1993 | 325 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 457 | 0.070 |
Why?
|
| Quinoxalines | 1 | 1986 | 39 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2013 | 12368 | 0.070 |
Why?
|
| Endothelium, Vascular | 3 | 1995 | 520 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 798 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 721 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 680 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2789 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1101 | 0.060 |
Why?
|
| Up-Regulation | 2 | 1997 | 862 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 373 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 3 | 1999 | 26 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1643 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2003 | 17 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2006 | 348 | 0.050 |
Why?
|
| Histamine Antagonists | 2 | 1997 | 16 | 0.050 |
Why?
|
| Cardiac Output, Low | 1 | 2003 | 67 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 681 | 0.050 |
Why?
|
| Ventricular Function, Left | 3 | 1997 | 506 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1394 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2006 | 434 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2003 | 101 | 0.050 |
Why?
|
| Creativity | 1 | 2002 | 13 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cyclic AMP | 2 | 2015 | 246 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 75 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 812 | 0.050 |
Why?
|
| Heart Rate | 3 | 2020 | 590 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2022 | 49 | 0.050 |
Why?
|
| Luciferases | 1 | 2022 | 132 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2022 | 56 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2013 | 311 | 0.050 |
Why?
|
| Blood Pressure | 4 | 2020 | 1351 | 0.050 |
Why?
|
| Prostaglandin D2 | 1 | 2001 | 9 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2001 | 41 | 0.050 |
Why?
|
| Macrophages, Peritoneal | 1 | 2001 | 37 | 0.050 |
Why?
|
| Methiothepin | 2 | 1992 | 2 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2001 | 64 | 0.050 |
Why?
|
| Canada | 1 | 2021 | 286 | 0.040 |
Why?
|
| Pressoreceptors | 1 | 2000 | 10 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2022 | 325 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 232 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2001 | 67 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2001 | 82 | 0.040 |
Why?
|
| Reflex | 1 | 2000 | 51 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2020 | 2580 | 0.040 |
Why?
|
| Adrenergic Agents | 1 | 2020 | 12 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 29 | 0.040 |
Why?
|
| Heart Atria | 1 | 2002 | 316 | 0.040 |
Why?
|
| Bioreactors | 1 | 2020 | 38 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2020 | 87 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2020 | 102 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 217 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 154 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2002 | 762 | 0.040 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 1999 | 11 | 0.040 |
Why?
|
| Maze Learning | 1 | 2020 | 128 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 549 | 0.040 |
Why?
|
| Receptors, Nicotinic | 1 | 2000 | 154 | 0.040 |
Why?
|
| Middle Aged | 2 | 2010 | 26812 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2020 | 71 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 78 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 436 | 0.040 |
Why?
|
| Kinetics | 2 | 2020 | 1323 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 263 | 0.040 |
Why?
|
| Protein Conformation | 2 | 1997 | 830 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 246 | 0.040 |
Why?
|
| Histamine Agonists | 1 | 1997 | 2 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2020 | 177 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 134 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 662 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 376 | 0.040 |
Why?
|
| Receptors, Histamine H2 | 1 | 1997 | 12 | 0.040 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2017 | 3 | 0.040 |
Why?
|
| Thiazoles | 2 | 2013 | 98 | 0.040 |
Why?
|
| Receptor Aggregation | 1 | 1997 | 7 | 0.040 |
Why?
|
| CHO Cells | 1 | 1997 | 160 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1997 | 152 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 29 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 1998 | 79 | 0.040 |
Why?
|
| Adenylyl Cyclases | 2 | 1995 | 83 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2017 | 107 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1997 | 185 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 313 | 0.030 |
Why?
|
| Cricetinae | 1 | 1997 | 413 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 95 | 0.030 |
Why?
|
| Reserpine | 2 | 1987 | 12 | 0.030 |
Why?
|
| Peptides | 1 | 2020 | 795 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Polymers | 1 | 1997 | 107 | 0.030 |
Why?
|
| Cystamine | 2 | 1986 | 4 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2007 | 6150 | 0.030 |
Why?
|
| Gene Expression | 3 | 2015 | 1560 | 0.030 |
Why?
|
| Clonidine | 2 | 1986 | 36 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 9033 | 0.030 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 13 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Fetal Heart | 1 | 1996 | 115 | 0.030 |
Why?
|
| Aspergillus niger | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pindolol | 1 | 1995 | 8 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1997 | 461 | 0.030 |
Why?
|
| Fish Oils | 1 | 1995 | 83 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 252 | 0.030 |
Why?
|
| Muscle Relaxation | 2 | 1993 | 16 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 47 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2746 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1993 | 238 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 564 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 310 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 15 | 0.030 |
Why?
|
| Allergens | 1 | 2015 | 252 | 0.030 |
Why?
|
| Molsidomine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Sydnones | 1 | 1993 | 1 | 0.030 |
Why?
|
| Organ Size | 3 | 2003 | 430 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 314 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 82 | 0.030 |
Why?
|
| Vasoconstriction | 2 | 1993 | 101 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 198 | 0.030 |
Why?
|
| Hypertension | 1 | 2001 | 1323 | 0.020 |
Why?
|
| Androgens | 1 | 2014 | 274 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 19317 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1883 | 0.020 |
Why?
|
| Analgesics | 1 | 1993 | 134 | 0.020 |
Why?
|
| Sympathetic Nervous System | 2 | 1989 | 63 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 1952 | 0.020 |
Why?
|
| Benzopyrans | 1 | 1991 | 19 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 354 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1993 | 204 | 0.020 |
Why?
|
| Piperazines | 1 | 1993 | 236 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 502 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1017 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1993 | 350 | 0.020 |
Why?
|
| Myosins | 3 | 1995 | 46 | 0.020 |
Why?
|
| Dihydroalprenolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| United States | 1 | 2005 | 10898 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1284 | 0.020 |
Why?
|
| Body Weight | 3 | 2003 | 990 | 0.020 |
Why?
|
| Sumatriptan | 1 | 1989 | 2 | 0.020 |
Why?
|
| Metergoline | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenoxybenzamine | 1 | 1989 | 12 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 1989 | 48 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 940 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 1061 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 875 | 0.020 |
Why?
|
| Perfusion | 1 | 1989 | 203 | 0.020 |
Why?
|
| Membrane Potentials | 3 | 1995 | 305 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1701 | 0.020 |
Why?
|
| Dogs | 3 | 1993 | 768 | 0.020 |
Why?
|
| Brimonidine Tartrate | 1 | 1986 | 4 | 0.020 |
Why?
|
| Idazoxan | 1 | 1986 | 2 | 0.020 |
Why?
|
| Nordefrin | 1 | 1986 | 2 | 0.020 |
Why?
|
| Dioxanes | 1 | 1986 | 5 | 0.020 |
Why?
|
| Yohimbine | 1 | 1986 | 18 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3334 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1986 | 257 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1995 | 51 | 0.010 |
Why?
|
| Fenoterol | 1 | 2003 | 1 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2003 | 12 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2003 | 28 | 0.010 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 28 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2003 | 53 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 2003 | 21 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2003 | 65 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2003 | 21 | 0.010 |
Why?
|
| Angiotensin I | 1 | 2003 | 10 | 0.010 |
Why?
|
| Losartan | 1 | 2003 | 36 | 0.010 |
Why?
|
| Renin | 1 | 2003 | 93 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 55 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2003 | 2812 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2003 | 61 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2003 | 19 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2003 | 39 | 0.010 |
Why?
|
| Gene Transfer Techniques | 2 | 1995 | 356 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 427 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2003 | 181 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2003 | 164 | 0.010 |
Why?
|
| Dinoprost | 2 | 1993 | 28 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2003 | 128 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 138 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 315 | 0.010 |
Why?
|
| Electrophysiology | 2 | 1993 | 270 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 2001 | 20 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2001 | 36 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 69 | 0.010 |
Why?
|
| Cyclopentanes | 1 | 2001 | 20 | 0.010 |
Why?
|
| Drug Interactions | 2 | 1993 | 254 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 1994 | 1327 | 0.010 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2000 | 58 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 2000 | 45 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 206 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 622 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 291 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1189 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 848 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 357 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2001 | 445 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 3038 | 0.010 |
Why?
|
| Atrial Function | 1 | 1997 | 13 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 1997 | 22 | 0.010 |
Why?
|
| Chimera | 1 | 1996 | 83 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 2821 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 132 | 0.010 |
Why?
|
| Fetal Death | 1 | 1996 | 112 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 657 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1995 | 24 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 1995 | 41 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1996 | 448 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 25 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 28 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 260 | 0.010 |
Why?
|
| Diglycerides | 1 | 1994 | 18 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 548 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1994 | 319 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 795 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1993 | 35 | 0.010 |
Why?
|
| Point Mutation | 1 | 1994 | 346 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 710 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 1586 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1993 | 60 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 2043 | 0.010 |
Why?
|
| Swine | 1 | 1995 | 1177 | 0.010 |
Why?
|
| Nebivolol | 1 | 1991 | 4 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1994 | 679 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1986 | 136 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1996 | 1815 | 0.000 |
Why?
|
| Pregnancy | 1 | 1996 | 7171 | 0.000 |
Why?
|